BRPI0514815A - método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica - Google Patents

método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica

Info

Publication number
BRPI0514815A
BRPI0514815A BRPI0514815-4A BRPI0514815A BRPI0514815A BR PI0514815 A BRPI0514815 A BR PI0514815A BR PI0514815 A BRPI0514815 A BR PI0514815A BR PI0514815 A BRPI0514815 A BR PI0514815A
Authority
BR
Brazil
Prior art keywords
treating
pharmaceutical composition
hyperproliferative skin
skin disorder
hyperproliferative
Prior art date
Application number
BRPI0514815-4A
Other languages
English (en)
Inventor
Joshua D Safer
Michael F Holick
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Publication of BRPI0514815A publication Critical patent/BRPI0514815A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODO PARA TRATAR UM DISTúRBIO DE PELE HIPERPROLIFERATIVA, E, COMPOSIçãO FARMACêUTICA. Refere-se ao uso de inibidores de conversão de hormónio de tireóide para tratar distúrbios de pele hiperproliferativa, preferivelmente ao seu uso em misturas tópicas.
BRPI0514815-4A 2004-09-01 2005-08-30 método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica BRPI0514815A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60648104P 2004-09-01 2004-09-01
PCT/US2005/030919 WO2006028835A2 (en) 2004-09-01 2005-08-30 Use of thyroid hormone conversion inhibitors

Publications (1)

Publication Number Publication Date
BRPI0514815A true BRPI0514815A (pt) 2008-06-24

Family

ID=36036840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514815-4A BRPI0514815A (pt) 2004-09-01 2005-08-30 método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica

Country Status (13)

Country Link
US (1) US20090082451A1 (pt)
EP (1) EP1789032A4 (pt)
JP (1) JP2008511660A (pt)
KR (1) KR20070083612A (pt)
CN (1) CN101090740A (pt)
AU (1) AU2005282789A1 (pt)
BR (1) BRPI0514815A (pt)
CA (1) CA2578999A1 (pt)
IL (1) IL181593A0 (pt)
MX (1) MX2007002451A (pt)
RU (1) RU2007111760A (pt)
WO (1) WO2006028835A2 (pt)
ZA (1) ZA200701800B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015366A2 (en) * 2007-07-26 2009-01-29 Trustees Of Boston University Use of thyroid hormone conversion inhibitors to treat hyperproliferative disorders
CA2810267A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
IT202100014333A1 (it) * 2021-06-01 2022-12-01 Materias S R L Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966967A (en) * 1973-03-21 1976-06-29 The Regents Of The University Of California Compositions and methods of treating psoriasis with vinyligs of desmethyl retinoic acid
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US4216224A (en) * 1978-09-22 1980-08-05 Scott Eugene J Van Methods and compositions for treating psoriasis with retinoyl compounds
JPS6044250B2 (ja) * 1981-10-02 1985-10-02 日本鉱業株式会社 亜砒酸の製造方法
DE3612305A1 (de) * 1986-04-11 1987-10-22 Roehm Pharma Gmbh Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere
TW218849B (pt) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5498636A (en) * 1992-03-13 1996-03-12 Ribogene, Inc. Treatment of angina pectoris
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
US6599448B1 (en) * 2000-05-10 2003-07-29 Hydromer, Inc. Radio-opaque polymeric compositions
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
EP1358175A2 (en) * 2001-02-08 2003-11-05 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
TW532210U (en) * 2002-02-20 2003-05-11 Chen-Wen Wang Locking device for a detachable skate of sports shoe
AU2003228819A1 (en) * 2002-05-03 2003-11-17 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
AU2003225305A1 (en) * 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Also Published As

Publication number Publication date
RU2007111760A (ru) 2008-10-10
ZA200701800B (en) 2008-09-25
EP1789032A4 (en) 2008-07-30
MX2007002451A (es) 2007-05-11
JP2008511660A (ja) 2008-04-17
AU2005282789A1 (en) 2006-03-16
KR20070083612A (ko) 2007-08-24
US20090082451A1 (en) 2009-03-26
IL181593A0 (en) 2008-06-05
CN101090740A (zh) 2007-12-19
EP1789032A2 (en) 2007-05-30
WO2006028835A2 (en) 2006-03-16
CA2578999A1 (en) 2006-03-16
WO2006028835A3 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
MEP31508A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
UY27720A1 (es) Aroilpiridinonas monocíclicas,
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
WO2009079451A3 (en) Compositions and methods of promoting wound healing
BRPI0816256A2 (pt) Uso de hidrofobina, e, processo para a preparação de um agente para a absorção melhorada de substâncias ativas no uso tópico
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
ME00226B (me) Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BRPI0514815A (pt) método para tratar um distúrbio de pele hiperproliferativa, e, composição farmacêutica
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
BRPI0922117A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético, método para realizar um tratamento terapêutico e/ou cosmético, uso de um aparelho, e, aparelho.
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus
BRPI0507912A (pt) método para o tratamento ou a prevenção de osteoporose em um indivìduo que sofra de renovação óssea aumentada, e, uso de um composto terapeuticamente ativo
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
WO2008063563A3 (en) Methods of treating keratin hyperproliferation disorders using mtor inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.